EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Efficacy of Immune Checkpoint Inhibitors in Combination With Platinum‐Based Doublet Chemotherapy for Extensive‐Stage Small‐Cell Lung Cancer Patients With Eastern Cooperative Oncology Group‐Performance Status 2–3: A Single‐Institution Retrospective Study

Kosuke Sakai iD, Shigeru Ishii, Shin Yokosuka, Tomoyuki Takahashi, Yuichiro Kawano, Hiroaki Nishimura, Yoshiki Kuwabara, Maiko Sasaki-Toda, Yumiko Ogawa-Kobayashi, Satoshi Kikuchi, Yusuke Hirata, Hiroyuki Kyoyama und 3 weitere

Cancer Medicine · 2025

DOI: 10.1002/cam4.71136 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2025. Verfasst von Kosuke Sakai und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary Medicine, Saitama Medical Center, Saitama Medical University, Saitama, Japan. Hauptthemen laut MEDLINE: Small Cell Lung Carcinoma, Immune Checkpoint Inhibitors, Lung Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The prognosis of small‐cell lung cancer (SCLC) remains poor, particularly in patients with extensive‐stage SCLC. The IMpower133 and CASPIAN trials revealed the efficacy of immune checkpoint inhibitors (ICIs) in extensive‐stage SCLC patients with good performance status (PS). The aim of this study was to investigate the efficacy of ICIs in patients with poor PS. Patients and Methods Patients with extensive‐stage SCLC who visited Saitama Medical Center, Saitama Medical University (Kawagoe, Japan) (September 2019–December 2022) were enrolled and followed up until February 2024. Objective response rate (ORR) and overall survival (OS) were compared between patients who received platinum‐based doublet chemotherapy with an ICI (atezolizumab or durvalumab; ICI group) and those treated with platinum‐based doublet chemotherapy alone (non‐ICI group). Results were stratified by the Eastern Cooperative Oncology Group performance status (ECOG‐PS) (i.e., 0–1 and 2–3).

Results

A total of 74 patients were included in the study (median OS: 327 days). In patients with ECOG‐PS 0–1, ORR was 76.5% and 56.5% in the ICI group ( n = 17) and non‐ICI group ( n = 23), respectively; OS was 406 and 379 days, respectively. In patients with ECOG‐PS 2–3, ORR was 93.3% and 56.3% in the ICI group ( n = 15) and non‐ICI group ( n = 16), respectively; OS was 446 days and 169 days, respectively. This evidence indicates that the addition of an ICI significantly improved OS ( p = 0.00661) and enhanced ORR.

Conclusion

In patients with extensive‐stage SCLC and ECOG‐PS 2–3, the addition of atezolizumab or durvalumab to platinum‐doublet chemotherapies improved the ORR, resulting in a better prognosis. These findings suggest that chemoimmunotherapy may be a feasible treatment option beyond the ideal clinical trial populations, addressing an unmet clinical need.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Small Cell Lung CarcinomaImmune Checkpoint InhibitorsLung NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsHumansMaleFemaleAgedRetrospective StudiesMiddle AgedNeoplasm StagingAntibodies, Monoclonal, HumanizedAdultAged, 80 and overTreatment OutcomePlatinumAntibodies, Monoclonal

Stichwörter der Autor:innen

anti‐PD‐L1 antibodiesatezolizumabdurvalumabextensive‐stage small‐cell lung cancerimmune checkpoint inhibitorperformance status

Substanzen

Immune Checkpoint InhibitorsdurvalumabAntibodies, Monoclonal, HumanizedatezolizumabPlatinumAntibodies, Monoclonal

Autor:innen und Institutionen

  • Department of Pulmonary Medicine, Saitama Medical Center, Saitama Medical University, Saitama, Japan.

ORCID-Profile: Kosuke Sakai, Nobuyuki Koyama, Kazutsugu Uematsu

Zitieren

APA

Sakai, K., Ishii, S., Yokosuka, S., Takahashi, T., Kawano, Y., Nishimura, H., Kuwabara, Y., Sasaki-Toda, M., Ogawa-Kobayashi, Y., Kikuchi, S., Hirata, Y., Kyoyama, H., Moriyama, G., Koyama, N., & Uematsu, K. (2025). Efficacy of Immune Checkpoint Inhibitors in Combination With Platinum‐Based Doublet Chemotherapy for Extensive‐Stage Small‐Cell Lung Cancer Patients With Eastern Cooperative Oncology Group‐Performance Status 2–3: A Single‐Institution Retrospective Study. Cancer Medicine. https://doi.org/10.1002/cam4.71136

Vancouver

Sakai K, Ishii S, Yokosuka S, Takahashi T, Kawano Y, Nishimura H, et al. Efficacy of Immune Checkpoint Inhibitors in Combination With Platinum‐Based Doublet Chemotherapy for Extensive‐Stage Small‐Cell Lung Cancer Patients With Eastern Cooperative Oncology Group‐Performance Status 2–3: A Single‐Institution Retrospective Study. Cancer Medicine. 2025. doi:10.1002/cam4.71136

BibTeX
@article{Sakai2025,
  author = {Sakai, Kosuke and Ishii, Shigeru and Yokosuka, Shin and Takahashi, Tomoyuki and Kawano, Yuichiro and Nishimura, Hiroaki and Kuwabara, Yoshiki and Sasaki-Toda, Maiko and Ogawa-Kobayashi, Yumiko and Kikuchi, Satoshi and Hirata, Yusuke and Kyoyama, Hiroyuki and Moriyama, Gaku and Koyama, Nobuyuki and Uematsu, Kazutsugu},
  title = {Efficacy of Immune Checkpoint Inhibitors in Combination With Platinum‐Based Doublet Chemotherapy for Extensive‐Stage Small‐Cell Lung Cancer Patients With Eastern Cooperative Oncology Group‐Performance Status 2–3: A Single‐Institution Retrospective Study},
  journal = {Cancer Medicine},
  year = {2025},
  doi = {10.1002/cam4.71136}
}
Kostenlos starten →